Seer Announces Receipt of Unsolicited Acquisition Proposal from Omid Farokhzad, M.D.
Rhea-AI Summary
Seer (Nasdaq: SEER) received an unsolicited, non-binding proposal from Chair and CEO Omid Farokhzad, M.D. to acquire all outstanding Class A common shares for $2.45 in cash per share plus two contingent value rights.
A Special Committee of independent directors will evaluate this proposal and other strategic alternatives with independent financial and legal advisors. No stockholder action is required now.
Positive
- All-cash offer of $2.45 per share plus two CVRs for Class A stock
- Independent Special Committee formed to review the proposal and alternatives
- Engagement of independent financial and legal advisors to support evaluation
Negative
- Acquisition proposal is unsolicited and non-binding, with outcome uncertain
- No timeline or guarantee that any transaction or alternative will be completed
Market reaction after CEO-led acquisition proposal: SEER +35.19% in the Jul 6 session
In the Jul 6 session, SEER gained 35.19%, reflecting a significant positive market reaction. Argus tracked a peak move of +50.0% during that session. Our momentum scanner triggered 20 alerts that day, indicating elevated trading interest and price volatility. Trading volume was exceptionally heavy at 24.0x the daily average, suggesting very strong buying interest.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Acquisition Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 27 | Acquisition campaign | Neutral | +2.1% | Radoff-JEC Group urged Seer to reevaluate its premium acquisition proposal. |
| May 14 | Acquisition proposal | Neutral | -1.1% | Radoff-JEC Group submitted its third non-binding proposal to acquire Seer. |
| Apr 29 | Proposal response | Neutral | -2.6% | Radoff-JEC Group responded after Seer rejected its April 24 acquisition proposal. |
| Apr 24 | Improved offer | Neutral | +1.6% | Radoff-JEC Group submitted an improved non‑binding proposal to acquire Seer. |
| Apr 13 | Initial offer | Neutral | +13.6% | Radoff-JEC Group made its initial non‑binding proposal to acquire Seer. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent acquisition-related headlines for Seer have typically produced modest single‑digit percentage moves, with one earlier proposal triggering a double‑digit gain.
Key Terms
contingent value rights financial
form 8-k regulatory
class a common stock financial
special committee regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
No Stockholder Action Required at This Time
REDWOOD CITY, Calif., July 02, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced that it has received an unsolicited, non-binding proposal from Omid Farokhzad, M.D., Seer’s Chair and Chief Executive Officer, to acquire all of the outstanding shares of Seer’s Class A common stock for
Seer’s Board of Directors will establish a Special Committee consisting solely of independent directors. The Special Committee will evaluate the Proposal and other alternatives available to Seer, and determine the course of action that it believes is in the best interests of Seer and its stockholders. The Special Committee will retain independent financial and legal advisors to assist it with its work.
No stockholder action is required at this time.
Perella Weinberg Partners LP is serving as financial advisor to Seer and Wilson Sonsini Goodrich & Rosati, Professional Corporation is serving as legal counsel.
About Seer, Inc.
Seer, Inc. (Nasdaq: SEER) sets the standard in deep, unbiased proteomics, delivering insights with a scale, speed, precision and reproducibility previously unattainable. Seer’s Proteograph® Product Suite integrates proprietary engineered nanoparticles, streamlined automation instrumentation, optimized consumables and advanced analytical software to overcome the limitations of traditional proteomic methods. Seer’s products are for research use only and are not intended for diagnostic procedures. For more information, visit www.seer.bio.
For more information, please email us at pr@seer.bio.
Forward Looking Statements
This communication contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Such forward-looking statements are based on Seer’s beliefs and assumptions and on information currently available to it on the date of this press release. Forward-looking statements may involve known and unknown risks, uncertainties and other factors that may cause Seer’s actual results, performance, or achievements to be materially different from those expressed or implied by the forward-looking statements. These statements include but are not limited to statements regarding the actions to be taken by the Board and the Special Committee. These and other risks are described more fully in Seer’s filings with the Securities and Exchange Commission and other documents that Seer subsequently files with the Securities and Exchange Commission from time to time. Except to the extent required by law, Seer undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.
Media Contact:
Patrick Schmidt
pr@seer.bio
Joele Frank, Wilkinson Brimmer Katcher
Eric Brielmann / Joseph Sala
(212) 355-4449
Investor Contact:
Marissa Bych
investor@seer.bio
